Anthera Pharmaceuticals, Inc. · Hayward, CA United States (NASDAQ: ANTH)
| 25801 Industrial Blvd. , Ste. B | Phone: 510-856-5600 |
| Hayward, CA | Fax: 510-856-5597 |
| 94545 | |
| United States | 
Map This Company |
Anthera Pharmaceuticals, Inc. Rankings
Company Description
Anthera Pharmaceuticals is involved in some very complicated sounding (not to mention hard to say) drug development. Its lead product, varespladib methyl, is in late stage clinical trials to treat acute coronary syndrome. Other candidates include A-623 to treat lupus and varespladib sodium to treat acute chest syndrome. Varespladib is designed to inhibit an enzyme called sPLA2 that is implicated in a variety of acute inflammatory conditions, such as cardiovascular disease, sickle cell disease, and coronary artery disease. Since its founding in 2004, Anthera's operations have consisted primarily of research and development activities. The company went public in early 2010 in an IPO worth about $37 million.
Anthera Pharmaceuticals, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: ANTH Single Location |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 25 |
Executives
20 executives listed for Anthera Pharmaceuticals, Inc.'s Hayward, CA location.
| Chairman | Christopher Henney | |
|---|---|---|
| President, CEO, and Director | Paul Truex | |
| CFO and VP Administration | Christopher Lowe |